KYTHERA BIOPHARMACEUTICALS INC (KYTH) [Rocket]

In millions, except per share items	Jun-30-15	Mar-31-15	Dec-31-14	Sep-30-14	Jun-30-14	Mar-31-14	Dec-31-13	Sep-30-13
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Product sales, net	0.3		132.4				50.5
Product sales, net growth			162.3%
Operating expenses:
Cost of sales	0.0
In-process research and development						52.8
Research and development	11.2	15.3	13.5	13.4	11.0	10.0	9.2	7.0
Selling, general and administrative	25.0	12.5	9.7	7.9	7.4	6.1	4.4	4.0
Total operating expenses	36.2	27.8	155.6	21.3	18.3	68.9	64.0	11.0
Loss from operations	-35.9	-27.8	-23.2	-21.3	-18.3	-68.9	-13.6	-11.0
Operating margin	100.0%		-17.5%				-26.9%
Interest income	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.0
Interest expense	-1.3	-1.1	-1.1	-1.2	-1.2	-0.7	-0.5	-0.5
Net loss	-37.2	-28.8	-24.2	-22.5	-19.5	-69.4	-14.0	-11.5

Other comprehensive income (loss):
Unrealized net loss on marketable securities	-0.1
Comprehensive loss	-37.3	-28.8	-24.2	-22.5	-19.5	-69.4	-14.0	-11.5

Per share information:
Net loss, basic and diluted (in dollars per share)	($1.44)	($1.24)	($1.07)	($0.99)	($0.86)	($3.18)	($0.66)	($0.62)

Basic and diluted weighted average shares outstanding (in shares)	25.9	23.2	22.5	22.7	22.7	21.8	19.2	18.7